VOTIS Subdermal Imaging Technologies Overview
VOTIS Subdermal Imaging Technologies is developing a suite of devices designed to help people with peripheral artery disease (PAD) preserve their feet. The companys PedCheck is used to screen the feet of asymptomatic patients for PAD. If PAD is found, then the PedStage will be used to stage and monitor disease progression and the impact of therapies prescribed by the patients physician. The PedFlo can be used during a revascularization procedure to inform the physician about the level of blood flow in the foot. All three VOTIS devices are safe, noninvasive, and free of ionizing radiation.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
VOTIS SUBDERMAL IMAGING TECHNOLOGIES, LTD. ANNOUNCES ENROLLMENT OF FIRST HUMAN SUBJECT IN PILOT FEASIBILITY STUDY OF PEDCHECK™ AT HADASSAH MEDICAL CENTER IN JERUSALEM
VOTIS Subdermal Imaging Technologies has enrolled the first patient in a feasibility study for its PedCheckTM device at Hadassah Medical Center in Jerusalem. The study aims to test the feasibility, usability, and safety of the device, which is designed to non-invasively measure Peripheral Arterial Disease (PAD) in the foot. The PedCheckTM directs light into the foot and measures its scattering and absorption to provide information about the location and severity of the disease. The study addresses the need for an efficient and accurate tool for PAD assessment, particularly in patients with diabetes. VOTIS is proud to begin the clinical trial at Hadassah Hospital, a leading medical center known for its use of advanced technology.
PartnersCustomers
growth-positive
Finding diabetic foot disease before symptoms show up
Israeli startup Votis has developed a noninvasive device that can identify peripheral artery disease in its early stages. The device assesses the blood and oxygen in the feet of people with diabetes, allowing for early detection and more treatment options. Votis plans to release the device in the US, Europe, and India in 2022 after completing medical trials and obtaining regulatory clearance. The company has raised $2.5 million in funding from investors in Israel, Britain, Italy, and the US. Votis aims to provide doctors and healthcare practitioners with a screening device that can be easily used and administered.
Customers
growth-positive
VOTIS Subdermal Imaging Technologies Raises US$2.5 Million
VOTIS Subdermal Imaging Technologies, Ltd. has raised US$2.5 million in a private placement of equity to a consortium of investors. The funds will be used to complete the development of the companys suite of medical devices and prepare for registration of the devices for sale in multiple countries. VOTIS plans to release its devices commercially in the US, Europe, and India in 2022. The companys devices are designed to help people with peripheral artery disease (PAD) by assessing blood flow and oxygen levels within the foot. The early diagnosis of PAD can lead to crucial treatment and potentially eliminate the need for amputation. PAD affects over 200 million people worldwide, with a significant economic burden in the US. VOTIS aims to address the challenge of early diagnosis and provide non-invasive solutions.
Investment
growth-positive
VOTIS Subdermal Imaging Technologies And ii Ventures Announce Plans To Develop Preventative Medicine Devices To Screen For Peripheral Artery Disease In India
VOTIS Subdermal Imaging Technologies, an Israeli corporation, and ii Ventures Private Limited, an Indian company, have entered into a memorandum of understanding to develop a system to screen the largely rural Indian population for peripheral artery disease (PAD). The devices will utilize the same technology that VOTIS is building into other devices intended for use in the US and Europe. The devices are non-invasive and do not use X-rays or other ionizing radiation. They are inexpensive and dependable. VOTIS plans to release its devices commercially in 2022.
PartnersExpand
growth-positive
VOTIS Subdermal Imaging Technologies Licenses Imaging Technology From Columbia University
VOTIS Subdermal Imaging Technologies has licensed an imaging technology from Columbia University to develop medical devices for peripheral artery disease (PAD) patients. The technology, called vascular optical tomographic imaging (VOTI), can identify problems with blood flow and oxygenation deep within the tissue of the foot. VOTIS plans to release its suite of devices commercially in 2022. PAD affects more than 200 million people worldwide, and early detection and treatment are crucial to reducing amputations and disabilities. The license grants VOTIS exclusive worldwide rights to the intellectual property, including 10 issued U.S. patents. The terms of the license were not disclosed.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8.07M |
| Last funding | $2.27M |
| Stage | A |
| Rounds | 6 |
| Investors | 2 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.votis.net |
Locations
Dostai Street 3, Jerusalem, Israel
Photos & Videos
1 item(s)
